Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.

Marc Garcia-MoureMarisol Gonzalez-HuarrizSara LabianoElisabeth GuruceagaEva BandresMarta Marija AlonsoLucia MarrodanCarlos de AndreaMaria VillalbaNaiara Martinez-VelezVirginia LaspideaMontse PuigdellosesJaime Gállego Pérez-LarrayaIgnacio Iñigo-MarcoRenata StripeckeJennifer A ChanEric H RaabeMarcel KoolCandelaria Gomez-Manzano Juan Fueyo Ana Patiño-García

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Delta-24-RGD is a feasible therapeutic option for AT/RTs and CNS-PNETs. This work constitutes the basis for potential translation to the clinical setting.

Keyphrases

blood brain barrier
single cell
human health
gene therapy
risk assessment
climate change